30 July 2018
EMA/375478/2018
EMEA/H/C/002332

Public statement

Victrelis

Withdrawal of the marketing authorisation in the European Union

On 29 June 2018, the European Commission withdrew the marketing authorisation for Victrelis (boceprevir) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Merck Sharp & Dohme Limited, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Victrelis was granted marketing authorisation in the EU on 18 July 2011 for treatment of chronic hepatitis C. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2016.

The European Public Assessment Report (EPAR) for Victrelis will be updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5520
Send a question via our website www.ema.europa.eu/contact